Skip to main content
Microbot Medical Inc. logo

Microbot Medical Inc. — Investor Relations & Filings

Ticker · MBOT ISIN · US59503A2042 LEI · 549300AEUNO16KTJXD72 US Manufacturing
Open in API
Filings indexed 1,062 across all filing types
Latest filing 2022-04-06 Board/Management Inform…
Country US United States of America
Listing US MBOT

About Microbot Medical Inc.

http://www.microbotmedical.com/

Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures with advanced robotic technology. The company researches, designs, and develops robotic endoluminal surgery devices for the minimally invasive surgery market. Its flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed to provide physicians with enhanced precision, control, and efficiency. Developed in collaboration with experts in Interventional Radiology, Neuroradiology, and Cardiology, the system aims to improve patient care and physician safety.

Recent filings

Filing Released Lang Actions
Board/Management Information 2022
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 1, 2022, by Microbot Medical Inc. The key content is the resignation of the previous CFO and appointment of a new CFO, Rachel Vaknin, including details of her employment agreement and compensation. The document also includes a press release about the promotion. The primary focus is on changes in senior management personnel, specifically the CFO position. There are no financial statements or detailed financial results presented, so it is not an earnings release or financial report. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-04-06 English
Annual Report 2021
Annual Report FY 2021
2022-03-31 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text mentions a press release about filing a pre-submission package with the FDA, which is furnished as an exhibit. The document is short (4064 characters) and primarily serves as an announcement of this event and the press release, not a full financial or operational report. There are no financial statements or detailed financial data presented. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-03-31 English
Board/Management Information 2022
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically details an amendment to the employment agreement of the CEO, including changes to his target bonus. This corresponds to a change in senior management terms rather than a full annual or quarterly report, earnings release, or other financial disclosures. The document is relatively short (3637 characters) and focuses on management changes, fitting the category of Board/Management Information (MANG).
2022-02-01 English
Director's Dealing 2022
Director's Dealing
2022-01-28 English
Director's Dealing 2022
Director's Dealing
2022-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.